JP2010502675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502675A5 JP2010502675A5 JP2009527141A JP2009527141A JP2010502675A5 JP 2010502675 A5 JP2010502675 A5 JP 2010502675A5 JP 2009527141 A JP2009527141 A JP 2009527141A JP 2009527141 A JP2009527141 A JP 2009527141A JP 2010502675 A5 JP2010502675 A5 JP 2010502675A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- pharmaceutically acceptable
- alkoxy
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 239000002253 acid Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 150000001412 amines Chemical class 0.000 claims 8
- 150000002148 esters Chemical class 0.000 claims 8
- -1 amino, mercapto Chemical class 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 238000010511 deprotection reaction Methods 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 125000001845 4 membered carbocyclic group Chemical group 0.000 claims 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- DCYAXQPTTJIWSG-UHFFFAOYSA-N 6-oxo-2-[4-(pyridin-3-ylsulfonylamino)phenyl]-2,5-dihydro-1h-pyridine-5-carboxylic acid Chemical compound N1C(=O)C(C(=O)O)C=CC1C(C=C1)=CC=C1NS(=O)(=O)C1=CC=CN=C1 DCYAXQPTTJIWSG-UHFFFAOYSA-N 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022680 Intestinal ischaemia Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010044541 Traumatic shock Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000001875 irritant dermatitis Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 231100000617 superantigen Toxicity 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 CC([C@]1C(*)C(N)=C**1)=**(*)=C(C)C(*)(*)N(*)* Chemical compound CC([C@]1C(*)C(N)=C**1)=**(*)=C(C)C(*)(*)N(*)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06120403 | 2006-09-08 | ||
| PCT/EP2007/059321 WO2008028937A1 (en) | 2006-09-08 | 2007-09-06 | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010502675A JP2010502675A (ja) | 2010-01-28 |
| JP2010502675A5 true JP2010502675A5 (enExample) | 2010-08-19 |
Family
ID=37708181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527141A Pending JP2010502675A (ja) | 2006-09-08 | 2007-09-06 | リンパ球相互作用が介在する疾患または障害を処置するために有用なｎ−ビアリール（ヘテロ）アリールスルホンアミド誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100029609A1 (enExample) |
| EP (1) | EP2081888A1 (enExample) |
| JP (1) | JP2010502675A (enExample) |
| KR (1) | KR20090060333A (enExample) |
| CN (1) | CN101511783A (enExample) |
| AR (1) | AR062677A1 (enExample) |
| AU (1) | AU2007293653B2 (enExample) |
| BR (1) | BRPI0716598A2 (enExample) |
| CA (1) | CA2662091A1 (enExample) |
| CL (1) | CL2007002607A1 (enExample) |
| MX (1) | MX2009002558A (enExample) |
| PE (1) | PE20080769A1 (enExample) |
| RU (1) | RU2009112719A (enExample) |
| TW (1) | TW200819418A (enExample) |
| WO (1) | WO2008028937A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2474545T (pt) | 2005-12-13 | 2017-02-14 | Incyte Holdings Corp | Pirrolo[2,3-b]piridinas e pirrolo[2,3-b]pirimidinas substituídas com heteroarilo como inibidores de janus quinase |
| GEP20125533B (en) | 2007-06-13 | 2012-05-25 | Incyte Corp | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentyl propanenitrile |
| JP5557832B2 (ja) * | 2008-03-18 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 置換４−ヒドロキシピリジン−５−カルボキサミド |
| KR20220084423A (ko) | 2008-07-23 | 2022-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체 |
| BRPI0917923B1 (pt) | 2008-08-27 | 2022-04-05 | Arena Pharmaceuticals Inc | Derivado de ácido tricíclico substituído, sua composição, seu uso e processo para preparar a referida composição |
| UY32349A (es) * | 2008-12-23 | 2010-07-30 | Novartis Ag | Derivados de biaril-bencil-amina |
| WO2010085968A1 (en) * | 2008-12-30 | 2010-08-05 | European Molecular Biology Laboratory (Embl) | Toluidine sulfonamides and their use as hif-inhibitors |
| HRP20140371T1 (hr) | 2009-05-15 | 2014-05-23 | Novartis Ag | Arilpiridini kao inhibitori sinteze aldosterona |
| HRP20192203T1 (hr) | 2009-05-22 | 2020-03-06 | Incyte Holdings Corporation | 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori |
| WO2010135650A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| AU2010331250B2 (en) * | 2009-12-16 | 2015-07-30 | Pola Chemical Industries Inc. | Preventing or ameliorating agent for pigmentation |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| PE20130038A1 (es) | 2010-03-10 | 2013-01-28 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de jak1 |
| US8835470B2 (en) | 2010-04-23 | 2014-09-16 | Bristol-Myers Squibb Company | Mandelamide heterocyclic compounds |
| RS54824B1 (sr) | 2010-05-21 | 2016-10-31 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| EP2619190B1 (en) | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| KR20140019300A (ko) | 2010-11-19 | 2014-02-14 | 인사이트 코포레이션 | Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체 |
| TWI477287B (zh) * | 2010-12-21 | 2015-03-21 | Pola Chem Ind Inc | 絲胺酸衍生物及製造色素沉澱之預防或改善劑之用途 |
| EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013126608A1 (en) | 2012-02-22 | 2013-08-29 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as tnap inhibitors |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| TWI761825B (zh) | 2012-11-15 | 2022-04-21 | 美商英塞特控股公司 | 盧梭利替尼之緩釋性劑型 |
| WO2014085453A2 (en) * | 2012-11-29 | 2014-06-05 | The Scripps Research Institute | Small molecule lxr inverse agonists |
| BR122021015061B1 (pt) | 2013-03-06 | 2022-10-18 | Incyte Holdings Corporation | Processos e intermediários para preparar um inibidor de jak |
| WO2015021153A1 (en) | 2013-08-07 | 2015-02-12 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| EP4445956A3 (en) | 2015-01-06 | 2024-12-04 | Arena Pharmaceuticals, Inc. | Compound for use in treating conditions related to the s1p1 receptor |
| EP3310760B8 (en) | 2015-06-22 | 2022-10-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物 |
| SG11201810837QA (en) | 2016-06-29 | 2018-12-28 | Univ Montreal | Biarylmethyl heterocycles |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| EP3582772A1 (en) | 2017-02-16 | 2019-12-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| PL3773593T3 (pl) | 2018-03-30 | 2024-09-02 | Incyte Corporation | Leczenie ropnego zapalenia gruczołów potowych z zastosowaniem inhibitorów jak |
| KR102859841B1 (ko) | 2018-06-06 | 2025-09-12 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 병태의 치료 방법 |
| KR102836433B1 (ko) | 2018-09-06 | 2025-07-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
| PH12022551033A1 (en) | 2019-10-31 | 2023-06-14 | Escape Bio Inc | Solid forms of an s1p-receptor modulator |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN114394946A (zh) * | 2022-02-21 | 2022-04-26 | 艾美科健（中国）生物医药有限公司 | 一种氟雷拉纳的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4315014A (en) * | 1980-09-24 | 1982-02-09 | Warner-Lambert Company | Antibacterial amide compounds and pharmaceutical composition containing the same |
| CA2473505A1 (en) * | 2002-02-07 | 2003-08-14 | Ellen M. Leahy | Novel bicyclic hydroxamates as inhibitors of histone deacetylase |
| WO2004024673A1 (en) * | 2002-09-13 | 2004-03-25 | Novartis Ag | Amino-propanol derivatives |
| US20050019746A1 (en) * | 2003-01-23 | 2005-01-27 | Eirx Therapeutics Limited | Apoptosis-related kinase/GPCRs |
| JP2007525406A (ja) * | 2003-12-04 | 2007-09-06 | ワイス | ビアリールスルホンアミドおよびその使用方法 |
| ES2348332T3 (es) * | 2005-09-16 | 2010-12-02 | Arrow Therapeutics Limited | Derivados de bifenilo y su uso en el tratamiento de la hepatitis c. |
-
2007
- 2007-09-06 MX MX2009002558A patent/MX2009002558A/es not_active Application Discontinuation
- 2007-09-06 AU AU2007293653A patent/AU2007293653B2/en not_active Expired - Fee Related
- 2007-09-06 RU RU2009112719/04A patent/RU2009112719A/ru not_active Application Discontinuation
- 2007-09-06 JP JP2009527141A patent/JP2010502675A/ja active Pending
- 2007-09-06 EP EP07803280A patent/EP2081888A1/en not_active Withdrawn
- 2007-09-06 CA CA002662091A patent/CA2662091A1/en not_active Abandoned
- 2007-09-06 CN CNA2007800331430A patent/CN101511783A/zh active Pending
- 2007-09-06 AR ARP070103934A patent/AR062677A1/es unknown
- 2007-09-06 BR BRPI0716598-6A2A patent/BRPI0716598A2/pt not_active IP Right Cessation
- 2007-09-06 PE PE2007001190A patent/PE20080769A1/es not_active Application Discontinuation
- 2007-09-06 WO PCT/EP2007/059321 patent/WO2008028937A1/en not_active Ceased
- 2007-09-06 KR KR1020097007129A patent/KR20090060333A/ko not_active Withdrawn
- 2007-09-06 US US12/440,143 patent/US20100029609A1/en not_active Abandoned
- 2007-09-07 TW TW096133616A patent/TW200819418A/zh unknown
- 2007-09-07 CL CL200702607A patent/CL2007002607A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010502675A5 (enExample) | ||
| RU2009112719A (ru) | Производные n-биарил(гетеро)арилсульфонамида, применимые в лечении заболеваний, опосредованных взаимодействием лимфоцитов | |
| JP6695360B2 (ja) | （ｒ）−および（ｓ）−１−（３−（３−ｎ，ｎ−ジメチルアミノカルボニル）フェノキシル−４−ニトロフェニル）−１−エチル−ｎ，ｎ’−ビス（エチレン）ホスホルアミデート、組成物ならびにその使用方法および製造方法 | |
| ES2568769T3 (es) | Derivados de piperazina y su uso como agentes terapéuticos | |
| JP6534650B2 (ja) | ロイコトリエンａ４加水分解酵素の阻害剤 | |
| ES2655971T9 (es) | Compuestos de aminopirimidinilo como inhibidores de JAK | |
| BRPI0611435A2 (pt) | derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos | |
| BR112015019634A2 (pt) | derivados de pirrolo[2,3-d]pirimidina como inibidores de janus kinase (jak) | |
| WO2011075334A1 (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| TW200806652A (en) | N-hydroxyacrylamide compounds | |
| JP2016513681A (ja) | ロイコトリエンａ４加水分解酵素の阻害剤 | |
| CA2928468A1 (en) | Novel dgat2 inhibitors | |
| JP2025121901A (ja) | ファルネソイドｘ受容体アゴニストの結晶質形態 | |
| AU2023346248A1 (en) | Heterocyclic sik inhibitors | |
| JP6416392B2 (ja) | ホスホリルコリン誘導体を含む分離物質 | |
| JP7296017B2 (ja) | ベンゾスルタムを含む化合物 | |
| JP2022046644A (ja) | マイコバクテリア感染症の処置のためのヘテロアリールトリフルオロボレート化合物 | |
| RU2817349C1 (ru) | Производные аминопиримидинила | |
| TWI782599B (zh) | 胺基嘧啶基衍生物 | |
| JP2013518846A5 (enExample) | ||
| KR20230100919A (ko) | 아미노피리미디닐 유도체 | |
| CN119212985A (zh) | Erk的吡咯抑制剂的氘代类似物、其合成及其中间体 | |
| WO2024115662A1 (en) | Small molecule modulators of il-17 | |
| JP2024109855A (ja) | ピロロ［２，３－ｄ］ピリミジン誘導体 | |
| JPWO2022157392A5 (enExample) |